iPSC-based research in ALS precision medicine

Letizia Mazzini; Fabiola De Marchi

doi:10.1016/j.stem.2023.05.008

iPSC-based research in ALS precision medicine

Cell Stem Cell. 2023 Jun 1;30(6):748-749. doi: 10.1016/j.stem.2023.05.008.

Authors

Letizia Mazzini¹, Fabiola De Marchi²

Affiliations

¹ ALS Centre, Neurology Unit, Department of Translational Medicine, Maggiore della Carità Hospital, University of Piemonte Orientale, Novara, Italy. Electronic address: letizia.mazzini@uniupo.it.
² ALS Centre, Neurology Unit, Department of Translational Medicine, Maggiore della Carità Hospital, University of Piemonte Orientale, Novara, Italy.

PMID: 37267911
DOI: 10.1016/j.stem.2023.05.008

Abstract

Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.

Publication types

Comment

MeSH terms

Amyotrophic Lateral Sclerosis* / therapy
Humans
Induced Pluripotent Stem Cells* / physiology
Motor Neurons
Precision Medicine